These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 38688656)
1. The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice. Kim KY; Kim YA; Joo HS; Kim JW In Vivo; 2024; 38(3):1127-1132. PubMed ID: 38688656 [TBL] [Abstract][Full Text] [Related]
2. Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury. Kosutova P; Mikolka P; Kolomaznik M; Balentova S; Adamkov M; Calkovska A; Mokra D Physiol Res; 2018 Dec; 67(Suppl 4):S645-S654. PubMed ID: 30607971 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice. Lee JM; Yeo CD; Lee HY; Rhee CK; Kim IK; Lee DG; Lee SH; Kim JW J Anesth; 2017 Jun; 31(3):397-404. PubMed ID: 28144780 [TBL] [Abstract][Full Text] [Related]
4. Protective effect of pravastatin on lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice. Yeo CD; Rhee CK; Kim IK; Kang HH; Lee SH; Lee SY; Kwon SS; Kim YK; Kim KH; Kim JW Exp Lung Res; 2013 Mar; 39(2):99-106. PubMed ID: 23368428 [TBL] [Abstract][Full Text] [Related]
5. LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing. Seehase S; Lauenstein HD; Schlumbohm C; Switalla S; Neuhaus V; Förster C; Fieguth HG; Pfennig O; Fuchs E; Kaup FJ; Bleyer M; Hohlfeld JM; Braun A; Sewald K; Knauf S PLoS One; 2012; 7(8):e43709. PubMed ID: 22952743 [TBL] [Abstract][Full Text] [Related]
6. Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Kim IK; Rhee CK; Yeo CD; Kang HH; Lee DG; Lee SH; Kim JW Crit Care; 2013 Jun; 17(3):R114. PubMed ID: 23787115 [TBL] [Abstract][Full Text] [Related]
8. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Cortijo J; Iranzo A; Milara X; Mata M; Cerdá-Nicolás M; Ruiz-Saurí A; Tenor H; Hatzelmann A; Morcillo EJ Br J Pharmacol; 2009 Feb; 156(3):534-44. PubMed ID: 19154443 [TBL] [Abstract][Full Text] [Related]
9. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor. Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526 [TBL] [Abstract][Full Text] [Related]
10. The Effect of Galantamine on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice. Kwon OB; Seo W; Kim KY; Joo H; Yeo CD; Kim JW In Vivo; 2024; 38(2):606-610. PubMed ID: 38418160 [TBL] [Abstract][Full Text] [Related]
11. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327 [TBL] [Abstract][Full Text] [Related]
12. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Buenestado A; Grassin-Delyle S; Guitard F; Naline E; Faisy C; Israël-Biet D; Sage E; Bellamy JF; Tenor H; Devillier P Br J Pharmacol; 2012 Mar; 165(6):1877-1890. PubMed ID: 21913898 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways. Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122 [TBL] [Abstract][Full Text] [Related]
14. Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis‑induced Acute Kidney Injury. Xu X; Liao L; Hu B; Jiang H; Tan M Med Sci Monit; 2020 May; 26():e921319. PubMed ID: 32449901 [TBL] [Abstract][Full Text] [Related]
15. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation. Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Pendrin by a small molecule reduces Lipopolysaccharide-induced acute Lung Injury. Lee EH; Shin MH; Gi M; Park J; Song D; Hyun YM; Ryu JH; Seong JK; Jeon Y; Han G; Namkung W; Park MS; Choi JY Theranostics; 2020; 10(22):9913-9922. PubMed ID: 32929324 [No Abstract] [Full Text] [Related]
17. Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway. Chang X; Hu LF; Ma XJ; Yin J; Liu XY; Li JB Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1335-1341. PubMed ID: 30779101 [TBL] [Abstract][Full Text] [Related]
18. miR-146b overexpression ameliorates lipopolysaccharide-induced acute lung injury in vivo and in vitro. He R; Li Y; Zhou L; Su X; Li Y; Pan P; Hu C J Cell Biochem; 2019 Mar; 120(3):2929-2939. PubMed ID: 30500983 [TBL] [Abstract][Full Text] [Related]
19. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on the lung functions in a saline lavage-induced model of acute lung injury. Kosutova P; Mikolka P; Kolomaznik M; Rezakova S; Calkovska A; Mokra D Physiol Res; 2017 Sep; 66(Suppl 2):S237-S245. PubMed ID: 28937238 [TBL] [Abstract][Full Text] [Related]
20. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]